[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@unsureoptimist UnsureOptimist

UnsureOptimist posts on X about $ntla, $capr, protocol, events the most. They currently have XX followers and X posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXX +253%
• X Month XXXXXX +85%
• X Months XXXXXX +992%
• X Year XXXXXX +444%

Mentions: X #

• X Months X no change
• X Year XX +500%

Followers: XX #

• X Week XX +2.10%
• X Month XX +5.30%
• X Months XX +71%
• X Year XX -XX%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence currencies XXXXX% finance XXXXX%

Social topic influence $ntla #8, $capr 11.11%, protocol 11.11%, events 11.11%, regulatory XXXXX%

Top accounts mentioned or mentioned by @doodaddoctor @norisknoparty

Top assets mentioned Intellia Therapeutics, Inc (NTLA)

Top Social Posts

Top posts by engagements in the last XX hours

"IMO: Given RMAT the longer the FDA takes: The more likely the review is becoming finalized not escalated The more data they are incorporating (autopsy labs risk window) The more solution-oriented the letter tends to be. Agree/Disagree $NTLA"
X Link 2025-11-24T15:04Z XX followers, 1137 engagements

"Just noticed Schwab switched $NTLA from ETB to HTB"
X Link 2025-12-01T19:11Z XX followers, 1280 engagements

"Binary event short squeeze for $NTLA Anyone see $CAPR It had XX million shares short or slightly less % of float than Intellia short. The potential is there"
X Link 2025-12-04T19:49Z XX followers, 1167 engagements

"Longer timelines typically happen when: FDA is analyzing full case details FDA + company are actively working on a revised protocol A path to resume is being shaped inside the letter itself Thats exactly what RMAT is designed to enable. $NTLA"
X Link 2025-12-05T22:15Z XX followers, XXX engagements

"If FDA intends to allow: no exclusions or only modest/targeted exclusions then ensuring no additional Grade X LFT events appear among the last-dosed patients gives the FDA: stronger statistical reassurance a defensible regulatory position $NTLA"
X Link 2025-12-05T22:25Z XX followers, XXX engagements

"Yowzers Approaching 40%. $ntla"
X Link 2025-12-10T04:16Z XX followers, XXX engagements